Report of Overseas Travel Minister for Health and Minister ......Minister for Health and Minister...

Report of Overseas Travel

Minister for Health and Minister for Ambulance Services

Trade Mission to USA and China

15 to 23 October 2016

Trade Mission USA and China

Travel Overview

Report to Parliament

This Report on overseas travel undertaken by the Minister for Health and Minister for Ambulance Services, Cameron Dick MP and his Senior Policy Adviser Mr Barnaby Kerdel, is tabled in accordance with Section 4.13.9 of the Ministerial Handbook. Travel Specifics: 1. Dates of Overseas Travel: Departure: Saturday 15 October 2016

Return: Sunday 23 October 2016 2. Destination: USA and China 3. Travel Plan: Brisbane – Los Angeles – Minneapolis – Shanghai – Hangzhou – Shenzhen – Brisbane 4. Participants: On 26 September, the Premier approved the Minister to travel to the USA and China from 15-23 October 2016 accompanied by his Senior Policy Adviser, Mr Barnaby Kerdel.

The Minister was also accompanied by Dr John Wakefield, Deputy Director-General Clinical Excellence Division, Department of Health (DoH) and Ms Tess Bishop, Executive Director, Office of the Director-General, DoH.

In China, Ms Angela Shi, Trade and Investment Queensland and Mr Jon Evans, Queensland Health’s China Consultant accompanied the delegation.

5. Acting Minister: The Minister for State Development and Minister for Natural Resources and Mines, and Member for Stafford, Dr Anthony Lynham MP, was acting Minister for Health and Minister for Ambulance Services for the period specified above.


Objectives

Promoting Queensland’s competitive advantages

The biomedical and life sciences sector in Queensland has been identified in

Advance Queensland as a priority sector to help diversify Queensland’s economy

and create new knowledge jobs.

There are major opportunities for knowledge-based industries growth in health

services and wellbeing exports from our state, including demand in the Asia-Pacific

region for the knowledge and skills of the Queensland health system and from the

broader health industry sector, including our research community.

The Queensland Government recognises it must help develop and facilitate these

opportunities and that now, more than ever, it is critical that government and

industry create dynamic partnerships in the push to increase Queensland’s export of

health services and products.

Queensland has many strategic advantages in applying its specific health know how

and providing premium health services globally.

Demand is growing in the Asia Pacific region, for example in the area of aged care

services in China. By 2020, China is expected to have 248 million people aged over

60 years. There is a strong focus on creating aged care beds, developing aged care

facilities, training health care workers and developing new models of care.

Queensland is well placed to take advantage of this, and other health related

economic and service opportunities.

Strengthening Queensland’s relationship with the USA

The trade mission to the USA focused on developing new connections and

facilitating further exchange of health and medical research information and

promoting Queensland’s expertise and skills, with a particular focus on:

– Advancing relationships developed by the Honourable Annastacia Palaszczuk

MP, Premier of Queensland and Minister for the Arts at BIO 2016, including

attending the AdvaMed Conference in Minneapolis

– Identifying and promoting opportunities and facilitating collaborations for

Queensland’s medical device and technology developers at AdvaMed

Queensland is a great location for health and life sciences research, development

and investment.

This trade mission to the USA provided representatives from Queensland’s research

community and innovative businesses with new technologies with the opportunity to

engage directly with global industry at AdvaMed.

Strengthening Queensland’s relationship with China

The focus of the trade mission to China was on developing new relationships and

facilitating further exchange of health and medical research information and promoting

Queensland’s expertise and skills.

A particular focus was on establishing new partnerships and opportunities for

collaboration with strategic and leading jurisdictions in China where health demand and

expenditure is growing exponentially and effective business relationships can be

developed.


Queensland is a great location for health and life sciences research, development

and investment.

Queensland has already made great strides in attracting the world’s best and

brightest to Queensland. Queensland recently welcomed BGI, one of the world’s

premier genomic research and development organisations with the announcement

of BGI’s Asia-Pacific HQ in Brisbane.

This trade mission to China provided representatives from Queensland-based health

business with the opportunity to engage directly with Chinese governments and

industry through health-dedicated conferences, trade fairs and business networking

functions.

Supporting the growth and development of the Queensland health industry means

increased exports and jobs for Queenslanders. We are committed to working closely

with our neighbours in China to develop more effective health care solutions while

enhancing and delivering on Queensland’s health and research export potential.

In the course of the trade mission we further advanced Queensland’s health

partnerships with our sister state Shanghai and with Brisbane’s sister city of

Shenzhen.

Opportunities were explored to learn from each other in:

– Remote care delivery systems and workforce development

– Tropical disease and communicable disease management

– Determining the active compounds that deliver the health benefits in Traditional

Chinese Medicine

– New digital health monitoring and care solutions

– New models of primary care and aged care and workforce development solutions

– Community based health care delivery systems

– New devices and pharmaceuticals

As the first Queensland Health Minister to visit China, I sought to develop critical

government to government relationships and open doors to more effective trade and

investment opportunities for our health and related sector to drive greater economic

development and sustainability, more innovative solutions and better health

outcomes for Queenslanders

The Asia-Pacific region is the fastest growing healthcare market in the world

The Association of Southeast Asian Nations (ASEAN) represents 600 million people

and is one of the fastest growing regions in the world and enormous market in close

proximity with enormous opportunities particularly for Queensland.

Expenditure on healthcare in ASEAN is expected to grow at over eight per cent

annually.

In China, the country's annual expenditure is projected to grow at an average rate of

11.8 percent a year in 2014-18, reaching $892 billion by 2018.

The opportunity for us is undeniable and through effective partnerships, particularly

across the Asia Pacific, we have the ability to co-invest in new health care solutions

that will help all our communities.

This mission to China identified, developed and consolidated these relationships at

a government to government, government to business and business to business

level.


Advancing health 2026

The Queensland Government through Advance Queensland is committed to

advancing the knowledge industries of Queensland.

Queensland’s economic and social prosperity is reliant upon the health of our

people. Our health system is ranked among the best in the world however like many

health systems globally, we do face significant challenges such as ageing

populations, high rates of obesity, increased chronic conditions such as cancer,

mental illness and diabetes.

If Queensland’s health system is to continue to rank amongst the best in the world it

has to rise to these challenges and embrace new opportunities, create new

partnerships, work in new ways, and innovate to generate new health solutions

Advancing Health 2026 was developed to respond to these challenges and

opportunities and we have a very clear vision for the future of health in Queensland:

By 2026 Queensland will be among the healthiest and productive people in the

world.

Advance Queensland

Advance Queensland is a comprehensive suite of programs designed around

international evidence of ‘what works’, designed to create the knowledge-based jobs

of the future.

The programs will drive innovation, build on our natural advantages and help raise

our profile as an attractive investment and development destination.

Advance Queensland will position Queensland as a place where entrepreneurs,

industry, universities and government collaborate to turn great ideas into commercial

products and enterprises that create jobs and wealth.

Accelerating Advance Queensland includes investing $405 million over four years to

create the knowledge-based jobs of the future:

– The Advance Queensland initiative includes a series of programs designed to

reinvigorate science and innovation to help create the well-paid, knowledge

based jobs of the culture which will attract and retain world-class scientific and

entrepreneurial talent.

– We are building an environment where collaboration between industry and

research bodies successfully translates ideas and research into commercial

outcomes, new and growing businesses and jobs. This will help make

Queensland a destination of choice for businesses looking to partner with

industry savvy researchers.

– We are boosting our entrepreneurial culture by improving access to finance, new

business opportunities, and management support for start-ups and small to

medium enterprises.

The new Integrated Care Innovation Fund of $35 million was established in 2016 to

focus on:

– ensuring patient care is integrated across Hospitals and Health Services , primary

health networks and other community care providers

– delivering better cooperation between generalists and specialists.


New funding of $25 million for the Queensland Genomics Health Alliance brings

together Queensland universities, research institutes and health service providers

to:

– research how best to use genomic medicine to diagnose or manage patients with

specific conditions or diseases and build the capacity of the state’s health

services to integrate genomics into everyday healthcare

– Encourage collaboration between experts and industry, leading to practical

outcomes that can improve the health of Queenslanders

– Provide for the knowledge-based jobs of the future.


United States of America 15 to 17 October 2016

Official Party:

Minister for Health and Minister for Ambulance Services, Cameron Dick MP

Dr John Wakefield, Deputy Director-General, Clinical Excellence Division, DoH

Ms Tess Bishop, Executive Director, Office of the Director-General, DoH

Mr Barnaby Kerdel, Senior Policy Advisor to Minister for Health and Minister for Ambulance Services

Queensland Delegates

Name Title Organisation

Mr Mario Pennisi Chief Executive Officer Life Sciences Queensland Limited (LSQ)

Dr Dimity Dornan AO

Executive Director and Founder

Hear and Say

Prof Pankaj Sah (Los Angeles)

Director Queensland Brain Institute (QBI), The University of Queensland (UQ)

Mr John Kelly

(Los Angeles)

Deputy Director (Strategic) QBI, UQ

Mr Phil Rowell Director PwC

Mr Paul Barrett Chairman Diversionary Therapy Technologies Pty Ltd

Mr Mark Guthrie Operations Manager Diversionary Therapy Technologies Pty Ltd

Dr Daniel Timms President and Chief Technology Officer

BiVACOR Inc

Professor Ian Wronski

Deputy Vice Chancellor Division of Tropical Health and Medicine, James Cook University (JCU)


Saturday 15 October 2016

08.20 - 09.00

Brisbane International Airport meeting with QBI

10.00 - 07.00

Transit Brisbane to Los Angeles (cross international date line)

07.00 - 08.00

Los Angeles Airport meeting with QBI and Boston Scientific Executives

09.45 - 17.00

Transit Los Angeles to Minneapolis

Sunday 16 October 2016

11.30 - 14.00 Meeting and official opening of Admedus Minneapolis office

17.30 - 18.30

Address AdvaMed 2016 International Reception

19.00 - 20.30

Minister’s Queensland Reception

Monday 17 October 2016

07.00– 09.30

Queensland Industry Breakfast

END OF USA PROGRAM


SATURDAY 15 OCTOBER

Meeting With Queensland Brain Institute

Brisbane Airport

MEETING ATTENDEES

Name

Professor Pankaj Sah

Director, QBI, UQ

Mr John Kelly Deputy Director (Strategic), QBI, UQ

Mr Mario Pennisi CEO, Life Sciences Queensland

Official Queensland Delegation Minister for Health and Minister for Ambulance Services, Cameron Dick MP



Mr Barnaby Kerdel, Senior Policy Adviser to Minister for Health and Minister for Ambulance Services

The University of Queensland’s Queensland Brain Institute (QBI) briefed me on

opportunities to establish a research centre focused on neural bio-engineering.

Director Professor Sah and Deputy Director Mr Kelly discussed Queensland’s

advantages in clinical service delivery, advanced medical research, and leadership in

key areas of health science and the opportunities to link with major international

partners.


SATURDAY 15 OCTOBER

Meeting With Queensland Brain Institute and Boston Scientific

Los Angeles Airport

MEETING ATTENDEES

Name

Professor Pankaj Sah

Director, QBI, UQ

Mr John Kelly Deputy Director (Strategic), QBI

Mr Milad Girgis Vice President Global Deep Brian Stimulation (DBS) and Program Management Boston Scientific

Mr Mario Pennisi CEO, LSQ

Official Queensland Delegation Minister for Health and Minister for Ambulance Services, Cameron Dick MP




At Los Angeles Airport, I met with Boston Scientific Neuromodulation’s Vice President,

Global Deep Brain Stimulation, Mr Milad Girgis and QBI to discuss possible

opportunities to establish a joint research centre in Queensland. The new centre would

engage industry with Queensland universities with a view to developing new

technologies to meet clinical challenges using advances in the space of neural bio

engineering.

I took the opportunity to provide Boston Scientific with an overview of Queensland’s

advantages in advanced medical research, development and manufacturing.

We also discussed the Queensland Government’s commitment to innovation, including

$405M committed to the Advance Queensland initiative.

I extended an invitation to Boston Scientific representatives to visit Queensland to see

our natural and intellectual assets first hand.


SUNDAY 16 OCTOBER

Meeting and official opening

Admedus Minneapolis office

ATTENDEES

Wayne Paterson Chair, Admedus

John Seaberg Non-executive Director, Admedus

Mario Pennisi CEO, LSQ

Official Delegate Party Minister for Health and Minister for

Ambulance Services, Cameron Dick MP




Along with the Queensland official party, I travelled to the office of Admedus – which is

an ASX listed public company expanding into the USA.

At the Admedus Minneapolis office, I met with Mr Wayne Patterson, Chair, Admedus,

who provided an update on growth of the business.

Mr Paterson outlined how Admedus is relocating its corporate service functions from

Perth to Brisbane, combining finance, human resources, IT, logistics and customer

service with the commercial headquarters for its infusion division and CardioCel©.

This technology is being used by surgeons at medical centres throughout

Australia,Europe, the US, Canada and Asia to treat complex heart defects, repair

congenital heart deformities and reconstruct heart valves.

Mr Paterson also outlined Admedus’s new research and product portfolio plans.


I took the opportunity to outline the goals and benefits of the Queensland

Government’s $405 million Advance Queensland initiative and discussed how

Admedus can continue to work with the research community in Queensland.

I was then invited to meet with around 20 Admedus staff, including many from

Queensland and other parts of Australia.

Over lunch, Mr Paterson and Admedus staff gave further detail on the activities, plans

and achievements of the company.

Following lunch, Mr Paterson and I conducted a ribbon cutting ceremony to open the

new premises.

I provided a short speech that emphasised the partnership between our two countries

and our hope for a strong relationship into the future.

NB: Following the trade mission, Mr Paterson and I opened the Brisbane office of

Admedus on Wednesday, 9 November 2016.


Address AdvaMed 2016 International Reception

Hilton Minneapolis

ATTENDEES

Attendees consisted of an mix of international medical devices companies, research institutes, universities and venture capitalist and Medical Technology investors

Official Party Minister for Health and Minister for





I hosted and met with a range of delegates to the Advamed Conference International Reception, one of the first events of the formal program. I provided a keynote address to welcome attendees to the conference. I took the opportunity to profile Queensland as a destination of choice for innovation and investment, particularly in healthcare services, research and medical devices. I also outlined possibilities for delegates to strengthen US/Queensland relationships in health research and innovation. Key points of my address included:

This is Queensland’s first delegation to the annual AdvaMed conference, leading the first international trade and investment mission by a Queensland Minister for Health.

Introduction of Queensland delegates, including representatives from medical devices organisations, Hear and Say, Diversionary Therapy Technologies, and BiVACOR Incorporated, as well as James Cook University.

AdvaMed presents an important opportunity to build new, strong and productive international relationships.

Queensland has developed an international reputation for science and research excellence.

Queensland’s reputation is driven by world-class institutions and infrastructure, consistent and genuine Government support, renowned researchers, and a track record of transformational breakthroughs,


Queensland’s natural assets are augmented by outstanding health service, clinical and medical research assets.

The Queensland Government is determined to create the right conditions for innovation to flourish in our state.

Through our $405 million Advance Queensland policy initiative, we have been providing unprecedented support to our start-ups and entrepreneurs, investing in world-class research talent and funding cutting-edge applied research projects that are founded on strong research-industry collaborations.

Queensland provides a secure, agile, and dynamic environment for research and industry collaborations and we are here to explore new opportunities with you.

The Queensland Government is committed to working with new partners in new ways to build the strong international relationships, needed to translate great ideas into great commercial outcomes.

Before and after the speech, I also met a number of individual delegates. I took the opportunity to point out benefits of investing in Queensland, our Advance Queensland policies, and features of our advanced health and medical research industry.


Minister’s Queensland Reception

W Hotel Minneapolis






Attendees:

Mr Mario Pennisi, CEO, LSQ

Dr Dimity Dornan AO, Executive Director and Founder, Hear and Say

Mr Phil Rowell, Director, PwC

Mr Paul Barrett, Chairman, Diversionary Therapy Technologies Pty Ltd

Mr Mark Guthrie, Operations Manager, Diversionary Therapy Technologies Pty

Ltd

Dr Daniel Timms, President and Chief Technology Officer, BiVACOR Inc

Professor Ian Wronski, Deputy Vice Chancellor, Division of Tropical Health and

Medicine, JCU

Mr Wayne Paterson, Chair, Admedus

Dr Scott Bliss, Director of Technical Operations, Admedus

Mr Ralph F. Ives, Executive Vice President, Global Strategy & Analysis,

AdvaMed

Mr Kenneth Mendez, Chief Revenue Officer, AdvaMed

Mr Zach Helzer, Associate Vice President, Global Strategy & Analysis, AdvaMed

Mr Matt Gardner, Founder and CEO, California Technology Council

Mr Andrew Wiltshire, Senior Director, Corporate Affairs, Medtronic

Mr Leighton Read, Venture Partner, Brandon Capital

Professor William E. Cohn, Baylor College of Medicine

I hosted an invitation-only reception for AdvaMed attendees, to promote Queensland’s capabilities and advantages in life sciences and medical devices. The purpose of the reception was to promote discussion among guests to encourage an awareness of the life sciences industry’s capabilities in Queensland and new opportunities for engagement and industry development.


I provided an opportunity for Queensland delegates to outline their role, links, and

potential synergies with other guests.

In my address to the reception, I outlined the significant opportunities and benefits that

can be accessed through the $405 million Advance Queensland policy initiative.

I also outlined how the Queensland Government is taking an active approach to

research and innovation, aiming to break down barriers and open doors to

collaboration and investment.

I indicated that, through Advance Queensland, the Queensland Government is

providing unprecedented support to start-ups and entrepreneurs, and is investing in

world-class research talent.

I also discussed with attendees Queensland’s key advantages in research, health and

knowledge precincts.

I was also pleased to update guests with the details of Queensland Health’s on

spending on services, and the Government’s intention to leverage that investment to

promote new jobs and innovation.

Along with other attendees, we discussed Advance Queensland’s links to previous

Queensland Government programs, including Smart State.

We also discussed the importance of advanced medical device manufacturing to the

Queensland economy and opportunities for Queensland to participate in medical

device supply chain.

Attendees also discussed opportunities to leverage Queensland as a base into

developing markets, such as the Asia Pacific including China.


MONDAY 17 OCTOBER

Queensland Industry Breakfast

Minneapolis Convention Centre






Attendees:

Mr Mario Pennisi (organiser), CEO, LSQ

Dr Dimity Dornan AO, Executive Director and Founder, Hear and Say

Mr Phil Rowell,Director PwC

Mr Paul Barrett, Chairman, Diversionary Therapy Technologies Pty Ltd

Mr Mark Guthrie, Operations Manager, Diversionary Therapy Technologies Pty

Ltd

Dr Daniel Timms, President and Chief Technology Officer, BiVACOR Inc

Professor Ian Wronski, Deputy Vice Chancellor, Division of Tropical Health and

Medicine, JCU

Mr Wayne Paterson, Chair, Admedus

Dr Scott Bliss, Director of Technical Operations, Admedus

Dr Julian Chick, Chief Operating Officer, Admedus

Mr Ben Jensen, Chief HR & Technology Officer, Admedus

Mr Danny Zanardo, Regional Vice-President of Emerging Markets, Admedus

Dr Gilles Devillers, President and Founder, Neolys Diagnostics

Professor William E. Cohn, Baylor College of Medicine

Mr Mike Shaughnessy - Medical Device Consulting

Mr Jimmy Jackson, Senior Vice President of Public Policy, Biocom

I welcomed guests and profiled Queensland as a destination of choice for innovation

and investment, particularly in healthcare services and research.

I asked Mr Pennisi to facilitate a discussion between our delegates and guests to

encourage an awareness of the life sciences industry’s capabilities in Queensland and

new opportunities for engagement and industry development.


Delegates outlined the advantages and challenges they had experienced in conducting

research, developing products and commercialising.

We discussed pathways for research, development and commercialisation of medical

devices.

We also discussed areas of Australian tax policy, and incentives that can be utilised to

support growth of medical device research and innovation.

Attendees were interested in the regulatory environment for medical devices in

Queensland and expressed a keen interest in opportunities to streamline the regulatory

process for innovative medical devices, research and development.

We also discussed Advance Queensland.

In response to this discussion, Deputy Director-General John Wakefield outlined the

opportunity of utilising clinical infrastructure within Queensland Health to expedite

testing and roll out of advanced medical devices for development and testing.

In particular, we discussed the use of the Queensland Clinical Senate and clinical

networks.

I concluded the meeting by providing contact details for delegates to pursue the

relationships commenced at Advamed, and departed for transit to Shanghai.


China 18 to 23 October 2016

Official Party:

Minister for Health and Minister for Ambulance Services, Cameron Dick MP




Mr Jon Evans, China Consultant, QH

Ms Angela Shi, Trade and Investment Queensland, Shanghai Office

Queensland Trade Delegates

Name Title Organisation

Mr Mario Pennisi Chief Executive Officer Life Sciences Queensland Limited

Ms Sandra Thomson General Manager Residential Services and Chief Clinical Officer

Prescare

Ms Lisa Thompson General Manager, Community services

Prescare

Ms Lyn Davies Managing Director Tunstall Healthcare (will not continue past Hangzhou)

Mr Geoff Feakes CIO Tunstall Group

(will not continue past Hangzhou)

Mr Chris Bartlett Director PwC

Prof Ian Wronski Deputy Vice Chancellor Division of Tropical Health and Medicine, James Cook University

Prof Frank Gannon Director QIMR Berghofer, Medical Research Institute


Monday 17 October 2016 – Tuesday 18 October 2016

10.55 – 20.00 (+1 day)

Minneapolis – Shanghai (cross international date line)

Wednesday 19 October 2016

09.30 – 11.00

Meeting with Director-General of the Shanghai Municipal Commission of Health and Family Planning

11.20 – 12.30

Official Tour Borderless Innovation Centre

14.00 – 17.00

Transit to Hangzhou (Zhejiang Province)

18.00 – 20.00

Meeting with Director General and other officials from Zhejiang Health and Family Planning Commission.

Thursday 20 October 2016

08.15 – 10.00

Address Zhejiang International Health Industry Summit

10.30 – 11.00

Signing of of MOU between Queensland Health & the Zhejiang Health and Family Planning Commission Signing of MOU between Life Sciences Queensland and Zhejiang Council for Health Services Promotion (ZCHSP)

11.00 – 11.30 Working lunch with officials from Zhejiang Health and Family Planning Commission

11.30 – 17.30 Transit to Shenzhen (Guandong Province)


Friday 21 October 2016

09.00 – 10.00 Official tour of newly opened China National Gene Bank with Qld delegation

10.30 – 12.30

Meeting with BGI officials and informal lunch BGI Headquarters

14.00 – 15.00 Queensland Delegation Meeting

Saturday 22 October 2016

11.45-10.30 (+1 day)

Transit Shenzhen to Brisbane

Sunday 23 October 2016

10.30 Arrive Brisbane

NOTE: Due to the typhoon Haima landing 65km north of Shenzhen on Friday 21

October travel to Sichuan province planned for the afternoon Friday 21 October 2016

was removed from the official schedule.


WEDNESDAY 19 OCTOBER

Meeting with Deputy Director General

Shanghai Health and Family Planning Commission

ATTENDEES

Shanghai Municipal Commission of Health and Family Planning

Zhang Xiong, M.D., Ph.D. Deputy Director-General

Zhang Kang, Director Science and Education department

Wu Hong, Deputy Director, Medical Administration Department

Leng Xiliang,. Director Policy Research Office

Cai Chun, Deputy Director, Disease Control Department

Qio Huihang, Director, Foreign Affairs Department

Yuan Zhifeng, Foreign Affairs Office (Shanghai Municipal Government)

Queensland Delegates Prof Frank Gannon, QIMR

Ms Sandra Thomson, Prescare

Ms Lisa Thompson, Prescare

Mr Chris Bartlett, PwC

Ms Lyn Davies, Tunstall Healthcare

Mr Geoff Feakes, Tunstall Healthcare

Mr Mario Pennisi, LSQ

Prof. Ian Wronski, JCU

Official Party Minister for Health and Minister for Ambulance Services, Cameron Dick MP







I met with representatives from the Shanghai Municipal Health and Family Planning

Commission to discuss the proposed health-component of the Shanghai – Queensland

MOU and identified additional areas of future collaboration.

The Deputy Director-General of the Shanghai Health and Family Planning Commission

provided a presentation to the Queensland delegation, which included the following:

Arrangements in relation to health insurance and the essential drug scheme.

Reforms in relation to secondary hospitals which are being transformed into

rehabilitation and nursing institutions.

Arrangements being implemented for medical alliances between tertiary hospitals,

secondary hospitals and GPs.

Pilot of a family doctor system, placing family doctors as gatekeepers for health

activity.

The 1+1+1 scheme, where residents select a relevant tertiary hospital, secondary

hospital and community health centre to improve the therapeutic relationship.

Reform to large public hospitals, aiming to reduce the dependence of residents on

hospital based care and improved cost control.

The Government’s goal to build two international medical campuses into clusters

for high end medical services.

The training and development pathways for health workers.

The information technology environment, including integrated clinical record.

The challenge of the ageing population, with 30% of the population now aged over

60.

Strategies, including improved medical and nursing care for the elderly.

Strategies, including advanced institutions funded by social capital.

Plans to develop a full lifecycle health management system for all residents.

Challenges including urban and rural integration.

Plans to improve technical support for suburban medical institutions.


Opportunities in information technology, including smart terminals, cloud

computers, sensors and big data.

Internet based services for diagnosis and inquiry.

Integrated management and service platforms for healthcare.

The Deputy Director-General, Clinical Excellence Division, Dr Wakefield and I

responded by delivering a presentation on health services in Queensland.

We outlined:

- Advancing Health 2026 and our vision that by 2026 Queenslanders will be

among the healthiest people in the world;

- The facts and figures about the size of our State and our population; disease

burden; our challenges in providing services to our community; our hospital

system and facilities; and our research and innovation infrastructure.

Presentations were followed by discussions identifying areas of

collaboration/mutual benefit.

The Deputy Director-General of the Shanghai Municipal Health and Family Planning

Commission and I agreed on the need to deliver practical outcomes to our respective

communities.

Shanghai representatives sought further detail on approaches to managing costs of

drug costs in Queensland.

I asked Dr Wakefield to outline opportunities for collaboration.

Dr Wakefield outlined Queensland’s approach to drug costs which includes centralised

procurement, strong medical governance, and prioritised antibiotic control.

I also asked the CEO of the QIMR Berghofer Medical Research Institute, Professor

Frank Gannon, to outline opportunities for institutional collaboration on research and

clinical trials, which was welcomed by Shanghai representatives.


I agreed with the Deputy Director-General of the Shanghai Municipal Health and Family

Planning Commission on the importance of preventative health. Shanghai

representatives outlined the increase in diabetes and obesity.

Queensland and Shanghai agreed to prioritise further work and collaboration in line

with the Memorandum of Understanding

I also took the opportunity to invite the Deputy Director-General of the Shanghai

Municipal Health and Family Planning Commission and other representatives from the

Commission to attend the opening of the Sunshine Coast University Hospital in 2017.


Official Tour

Bordeless Innovation Centre, Shanghai

ATTENDEES

Chinese Official Dr Wei Siang Yu, Founder and Executive Chairman Borderless Healthcare Group

Queensland Delegates Prof Frank Gannon, QIMR Berghofer




Ms Lyn Davies,Tunstall Healthcare



Prof Ian Wronski, JCU







I led the Queensland contingent to meet Dr Wei, Chairman, Borderless Healthcare

Group, and to tour the Borderless Health Centre in Shanghai.

Dr Wei outlined the history of the centre, and his longstanding personal and

professional links to Australia.

Dr Wei outlined the Centre's role in facilitating the development of new and innovative

health care solutions between China and international partners.

Dr Wei outlined potential new aged care and primary care solutions to China’s key

health service delivery challenges.


Dr Wei also outlined opportunities as to how the delegates and Queensland

Government might most effectively partner with Chinese colleagues including specific

project opportunities within Western China.

Dr Wei outlined emerging opportunities utilising smart television, internet and other

technologies and the role these technologies would play in the future Chinese health

service delivery system

The Queensland delegates were advised on the critical elements to conducting

successful within the China context.

Along with other Queensland delegates, we discussed opportunities, challenges and

enablers to helping Queensland companies engage with China.

Following the discussion, Dr Wei took the Queensland delegation for a tour of the

Centre, including the in-house studio.


Meeting with Zhejiang Health and Family Planning Commission

Zhejiang Narada Grand Hotel

Chinese Officials Mr Yang Jing, Director-General, Zhejiang Health and Family Planning Commission

Mr Chen Zhengfang, Director, Department of International Cooperation, Zhejiang Commission of Health and Family Planning

Mr Cao Qifeng, Director, General Office, Zhejiang Commission of Health and Family Planning

Mr Zhu Yaochuan, President, Health Services Promotion Council of Zhejiang Province

Ms Ma Huanping, Section Chief, Department of International Cooperation, Zhejiang Commission of Health and Family Planning







The Director General, Zhejiang Health and Family Planning Commission welcomed the official party to the province, and provided an informal briefing.

I was briefed on the activities, challenges and strategies in Zhejiang province.

I was advised on the challenges that Zhejiang is facing in respect of an ageing

population, growth in demand for health services, and rapid development.

I took the opportunity to outline the how many of these challenges are also common to

Queensland.


The Director General was particularly interested in new developments in preventative

health.

I took the opportunity to outline the scope and benefits of the Queensland

Government’s world leading approach to smoking.

In particular, I spoke about the recent laws that were proposed and passed that

significantly increase the number of smoke free spaces in Queensland.

I was pleased to learn of the long relationship that Queensland has had with the

province in the past.

The Director General and his colleagues outlined how they felt that there were long

lasting benefits of the engagement, with many clinicians now working in Zhejiang

province who received training in Queensland.

I outlined, from Queensland’s perspective, that we too see many benefits in return from

the exchange with Zhejiang province.

We agreed that it would be important to renew this relationship, to continue to deliver

outcomes for our respective jurisdictions.


THURSDAY 20 OCTOBER

Address Zhejiang International Health Industry Summit (Special guest of the Director General of the Health and Family Planning Commission).

Zhejiang Narada Grand Hotel

ATTENDEES

Summit Attendees 500 senior government health officials, financial institutional investors, leading healthcare companies seeking opportunities to be involved in the development of the Zhejiang Health Industry

Mr Yang Jing, Director-General, Zhejiang Health and Family Planning Commission















At the invitation of Zhejiang province, I attended the Zhejiang International Health Industry Summit.

Prior to the meeting, I had the opportunity to meet with the Vice Governor of Zhejiang Province. We discussed the common challenges facing both Queensland and


Zhejiang. Mr Yang Jing was particularly interested in Queensland’s approach to the provision of ambulance services.

I then provided the keynote address to the summit.

Key points of my presentation included:

Close parallels between Queensland and Zhejiang, particularly in hosting the

G20.

History of mutual co-operation between our jurisdictions.

Shared challenges and solutions including ageing populations, mental illness,

and diabetes.

Opportunities through the China Australia Free Trade Agreement.

Queensland’s advantages, including investment in biotechnology and research

infrastructure.

The advantages of the $405 million Advance Queensland initiative.

Existing partnerships with China.

Queensland’s strong research and development record.

Tropical health expertise.

BGI’s partnership with the QIMR Berghofer Medical Research Institute.

Clinical trial facilities.

Integrated care through the public health system.

Digital hospital advancement.

Telehealth expertise.

Aged care and technology.

Clinical skills and training.

Following my speech, the Vice Governor of Zhejiang province hosted me and the Queensland delegates on a tour of the expo, during which I was able to speak with many of the exhibiters. I was particularly pleased to visit the Queensland Health booth, the first time that Queensland Health has had a presence at the expo. There was significant interest in our delegation from the media and exhibitors.


Meeting and with Director-General and officials

Zhejiang Health and Family Planning Commission

MEETING ATTENDEES

Chinese Officials Mr Yang Jing, Director-General, Zhejiang Health and Family Planning Commission

Mr Xu Runlong, Deputy Director-General, Zhejian Commission of Health and Family Planning

Mr Chen Zhengfang, Director, Department of International Cooperation, Zhejiang Commission of Health and Family Planning

Mr Zhu Yaochuan, President, Health Services Promotion Council of Zhejiang Province

Mr Mao Linan, Deputy Director, Healthcare International, Zhejiang

Ms Ma Huanping, Section Chief, Department of International Cooperation, Zhejiang Commission of Health and Family Planning
















I met with officials from the Zhejiang Health and Family Planning Commission in order to finalise an MOU with Queensland Health and to witness the signing of an MOU between Life Sciences Queensland and its industry counterpart Zhejiang Council for Health Services Promotion (ZCHSP). In the meeting with Zhejiang Health and Family Planning Commission I formally outlined the Government’s commitment to our renewed relationship. Representatives from the Commission outlined the significant growth and development of their activities, and opportunities for collaboration I emphasised that Queensland and Zhejiang share many health challenges – an ageing population, increasing chronic diseases such as cancer, mental illness and diabetes, rising healthcare costs, and the need to create more sustainable health care systems that are accessible to all. I outlined how the Queensland Government, in particular my Department of Health, and our health industry are committed to identifying opportunities for Queensland and Zhejiang to work together to develop health and aged care solutions. We discussed opportunities to match our health services and universities with potential partners as well as medical research that will underpin these new solutions. We discussed how the MOU between Queensland Health & the Zhejiang Health and Family Planning Commission will focus on:

Primary care service development and workforce training.

Aged care service development and workforce training.

New technology solutions to improve health care.

Communicable disease management.

Health service management.

I was pleased to see how Zhejiang provides a positive example of a provincial Government working in tandem with private industry and is progressive in the application of technology to enable new health care delivery solutions and the development of supporting technology platforms to engage consumers more directly in their care. We discussed how the MOU provides a framework and enables more direct government support for joint collaboration, which will in turn generate opportunities for increased health exports, investment attraction and knowledge creation based jobs.

We also discussed the opportunity for industry collaboration, in particular, how the MOU between Life Sciences Queensland and Zhejiang Council for Health Services provides a framework and supporting mechanism for direct business to business trade and development activities between Zhejiang Province and Queensland’s industry.

The meeting concluded with the signing of the MOUs. I have since learned that, following the signing of the MOU, the Zhejiang H&FPC is likely to send a delegation to Queensland in December 2016 to learn more about the application of the Casemix funding model.


FRIDAY 21 OCTOBER

Official tour, meeting, and MOU signing

China National Gene Bank and BGI Shenzhen

ATTENDEES

BGI Official Wang Jian, President

Yanmei Zhu, Executive Vice President

Dr Bicheng Yang, BGI, APAC Director







Mr Michael Mason, Think Queensland







In August 2016, the Deputy Premier announced BGI would be opening its Asia Pacific

research and commercialisation headquarters at the QIMR Berghofer Medical

Research Institute (QIMR Berghofer).

This is a significant vote of confidence in Queensland as a destination of choice for

health and medical research.

I was therefore very pleased to accept BGI’s invitation to visit the China National Gene

Bank (CNGB) in Shenzhen, which is a public-private partnership between BGI and the

Chinese government

As part of the tour, I was advised that only three other comparable gene banks exist

globally.


I, along with Queensland delegates, was provided with a detailed briefing of the history

and progress of gene sequence and storage.

The CNGB is a major contributor to the growing spectrum of gene banking.

Stage I of the CNGB Biorepository (costing US$117M) has capacity to store more than

10 million traceable bio-samples, including human, plant, animal and microbes.

When fully functioning, CNGB will become the world's largest and most comprehensive

gene bank with a collection of 300 million samples.

I was interested to hear how gene banking holds the promise to understand and solve

the genetic sources of many diseases.

These could potentially deliver life saving and life extending treatments that will benefit

Queenslanders and the world.

Following the tour, the Queensland delegation and I travelled to the Shenzhen

headquarters of BGI, where I was provided with an update on the global footprint of

BGI, including the new presence in Queensland.

I emphasised how the Queensland Government was looking to exciting future

economic and research opportunities that will result from BGI choosing Queensland for

its Asia Pacific research and development headquarters.

We discussed how the location of BGI in Queensland demonstrates strong confidence

in Queensland, the skills and capabilities of our research organisations and the

Palaszczuk Government’s Advance Queensland innovation agenda.

We also discussed how Queensland has been building a reputation for our leading

edge genomics research. Geographically, the co-location of BGI with QIMR Berghofer

at the Herston Health precinct in Brisbane is testament to the institute’s world class

reputation in genetics and bioinformatics.

I outlined that the Herston Health Precinct is a significant health ecosystem and will

allow BGI to work closely with our clinics and laboratories.

I also indicated that the Government is investing $25million in the Queensland

Genomics Health Alliance.

This Alliance brings together Queensland research institutes including QIMR Berghofer

to explore ways to harness the potential of genomics to improve patient care in a way

that is ethical, informed and cost effective.

Professor Frank Gannon also provided an update on ongoing work of QIMR Berghofer

with BGI, and there was discussion of next steps for the partnership


FRIDAY 21 OCTOBER

Queensland Delegation Meeting

Hilton Shenzhen Futian

ATTENDEES













At the conclusion of the official program, I convened a meeting of the Queensland

delegation to seek their views as on outcomes and next steps arising from the trade

mission.

Delegates agreed that there were significant opportunities in the Chinese market. In

particular, delegates highlighted possibilities for training and accreditation of clinicians

within Queensland. We discussed potential exchanges of staff and options for

providing recognised qualifications. Delegates recognised there are potential

opportunities in nursing, medical and allied health qualifications, and also for the

sharing of expertise in patient safety and quality.

Delegates also discussed extensively the opportunities for export of health treatment

and expertise into the Chinese market. Particularly for private healthcare, there are

significant opportunities for medical tourism, which could also deliver significant spin off

benefits. We also agreed there are significant opportunities for joint innovation and

collaboration to develop new intellectual property. Queensland and China have

significant capability, and delegates considered approaches to best manage this in the

future.

Delegates agreed the trip offered significant benefits for their respective stakeholders.

Report of Overseas Travel Minister for Health and Minister ......Minister for Health and Minister...

Documents

Transcript of Report of Overseas Travel Minister for Health and Minister ......Minister for Health and Minister...